Highlights

• Well, unfortunately only about 70% of my patients respond completely and achieve seizure freedom. So, it is an important unmet need to have medications that are effective for those 30% or even sometimes 40% of patients in my practice who are not responding fully.
• Well, cenobamate seems to have activity in patients that are refractory, and it can produce a high incidence of seizure freedom. So that has definitely been a positive for it, and I think that if it is approved, and we are not sure it is going to be approved because of the incidence of a serious skin rash, if it is approved it could be very interesting.
• Well, what I think is that it will perform probably similarly to other medications, assuming it does not have any surprising adverse effects, and what that means is that it will be a slow uptake. Ordinarily, antiepileptic drugs do not have a very strong usage outside of the gate, their launches are relatively slow, and then if the drug seems to perform well and it does not have much in the way of problems associated with it, it will get a strong and steady uptake over time.